Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS) Database
  • Print
  • Share
  • E-mail
-

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


           

REACH PAS


Suggest Enhancement / Report Issue | export reports to excelExport to Excel
General
Study Status Study Pending
Application Number /
Requirement Number		 P100042 S038/ PAS001
Date Original Protocol Accepted 02/03/2026
Date Current Protocol Accepted 02/03/2026
Study Name REACH PAS
Device Name APTIMA HPV ASSAY
General Study Protocol Parameters
Study Design Cross-Sectional Study
Data Source Other Data Source
Comparison Group Concurrent Control
Analysis Type Descriptive
Study Population Adult: At least 22 yrs
Detailed Study Protocol Parameters
Study Objectives To collect clinical data evaluating the clinical performance of the Aptima HPV Assay and the Aptima HPV 16 18/45 Genotype Assay compared to an HPV test that is FDA-approved for primary screening in women aged 25-29 years from CERVIVA Primary Screening Study, confirming the safety and effectiveness of the device in this specific age group.
Study Population All women aged 25 to 29 years presenting for cervical cancer screening.
Sample Size 1800 participants.
Key Study Endpoints The ratio (Aptima HPV Assay and Aptima HPV 16 18/45 Genotype Assay: FDA-approved HPV test) of clinical sensitivity and false positive rates for detection of CIN2+ and CIN3+.
Follow-up Visits and Length of Follow-up None


REACH PAS Reporting Schedule

Reporting Schedule
Report
Date Due
FDA Receipt
Date
Applicant's Reporting Status
6 month report 08/04/2026    
1 year report 02/03/2027    
2 year report 02/03/2028    
3 year report 02/02/2029    
4 year report 02/02/2030    


Contact Us
Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources

-
-